ClinicalTrials.gg
CompletedNCT01326026BEGIN™Updated Mar 6, 2017Results posted

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
46th of 70
222 · median 384
Started
2011
with 7 others
Phase 3
49 of 70
2 open now
Registered
19th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 46th largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 19th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different self-titration algorithms (dose individually adjusted) in combination with metformin.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 222 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (Visit 2)
  • Current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other OADs including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (TZDs) all with unchanged dosing for at least 12 weeks prior to randomisation (Visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily
  • 7.0-10.0% (both inclusive) by central laboratory analysis
  • (Body Mass Index) no higher than 45.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucagon-like peptide 1 (GLP-1) receptor agonist within the last 12 weeks prior to Visit 2
  • Suffer from a life threatening disease (e.g. cancer)
  • Females of who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hCG), breast feeding or intend to become pregnant or are not using adequate methods (adequate contraceptive methods as required by law or practise [for Germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal IUD, sexual abstinence or vasectomised partner])
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    IDeg Simple

    Drug: insulin degludec

  • Experimental
    IDeg Step wise

    Drug: insulin degludec

Interventions

  • Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

  • Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG after 26 weeks of treatment.

    Time frame: Week 0, Week 26

  2. Rate of Treatment Emergent Adverse Events (AEs)

    Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.

    Time frame: Week 0 to Week 26 + 7 days follow up

  3. Rate of Confirmed Hypoglycaemic Episodes

    Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Week 0 to Week 26 + 7 days follow up

  4. Rate of Nocturnal Confirmed Hypoglycaemic Episodes

    Observed rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

    Time frame: Week 0 to Week 26 + 7 days follow up

08

Results

Posted Nov 17, 2015

Participant flow

The trial was conducted at 43 sites in 4 countries: Finland (5), Germany (6), Spain (6) and United States of America (26).

Participant flow — Overall Study
MilestoneIDeg SimpleIDeg Step Wise
Started111111
Exposed110111
Completed9998
Not completed1213
Withdrew: Adverse event43
Withdrew: Withdrawal criteria57
Withdrew: Other33

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, Week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinIDeg SimpleIDeg Step Wise
Change in Glycosylated Haemoglobin (HbA1c)-1.09 ± 1.05-0.93 ± 0.97
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline in FPG after 26 weeks of treatment.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LIDeg SimpleIDeg Step Wise
Change in Fasting Plasma Glucose (FPG)-3.27 ± 3.56-2.68 ± 3.50
SecondaryRate of Treatment Emergent Adverse Events (AEs)

Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Events/100 years of patient exposure
Rate of Treatment Emergent Adverse Events (AEs)
Events/100 years of patient exposureIDeg SimpleIDeg Step Wise
Adverse events (AEs)346379
Serious AEs1515
Severe AEs1510
Moderate AEs6979
Mild AEs262291
Fatal AEs02
SecondaryRate of Confirmed Hypoglycaemic Episodes

Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDeg SimpleIDeg Step Wise
Rate of Confirmed Hypoglycaemic Episodes160117
SecondaryRate of Nocturnal Confirmed Hypoglycaemic Episodes

Observed rate of nocturnal confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

Time frame:
Week 0 to Week 26 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDeg SimpleIDeg Step Wise
Rate of Nocturnal Confirmed Hypoglycaemic Episodes2110

Adverse events

Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg Simple—5/110 (4.5%)17/110 (15.5%)
IDeg Step Wise—7/111 (6.3%)14/111 (12.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventIDeg SimpleIDeg Step Wise
Acute myocardial infarctionCardiac disorders2/1100/111
Atrioventricular block completeCardiac disorders1/1100/111
Coronary artery stenosisCardiac disorders1/1100/111
Gastrointestinal angiodysplasiaCongenital, familial and genetic disorders1/1100/111
VertigoEar and labyrinth disorders1/1100/111
Retroperitoneal haematomaGastrointestinal disorders1/1100/111
AstrocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1100/111
Arteriosclerosis coronary arteryCardiac disorders0/1101/111
Coronary artery occlusionCardiac disorders0/1101/111
BronchitisInfections and infestations0/1101/111
Most frequent other events
Most frequent other events
EventIDeg SimpleIDeg Step Wise
NasopharyngitisInfections and infestations10/1107/111
HeadacheNervous system disorders8/1108/111

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDeg SimpleIDeg Step WiseTotal
Mean59.4 ± 9.558.5 ± 11.158.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)IDeg SimpleIDeg Step WiseTotal
Female433679
Male6875143
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDeg SimpleIDeg Step WiseTotal
Mean8.1 ± 0.98.2 ± 0.98.1 ± 0.9
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDeg SimpleIDeg Step WiseTotal
Mean9.3 ± 2.69.4 ± 2.89.4 ± 2.7
09

Study locations

45 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35216, United States
  • Novo Nordisk Investigational Site
    Huntsville, Alabama 35801, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Mission Hills, California 91345, United States
  • Novo Nordisk Investigational Site
    National City, California 91950, United States
  • Novo Nordisk Investigational Site
    North Hollywood, California 91606, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Columbus, Georgia 31909, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59102, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Melrose Park, Pennsylvania 19027, United States
  • Novo Nordisk Investigational Site
    East Providence, Rhode Island 02914, United States
  • Novo Nordisk Investigational Site
    Humboldt, Tennessee 38343, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77095, United States
  • Novo Nordisk Investigational Site
    Killeen, Texas 76543-5600, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    Ogden, Utah 84403, United States
  • Novo Nordisk Investigational Site
    St. George, Utah 84790, United States
  • Novo Nordisk Investigational Site
    Helsinki, 00260, Finland
  • Novo Nordisk Investigational Site
    Kerava, FI-04200, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33210, Finland
  • Novo Nordisk Investigational Site
    Turku, 20520, Finland
  • Novo Nordisk Investigational Site
    Turku, FI-20100, Finland
  • Novo Nordisk Investigational Site
    Berlin, 12163, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Almería, 04001, Spain
  • Novo Nordisk Investigational Site
    Antequera, 29200, Spain
  • Novo Nordisk Investigational Site
    Gijón, 33206, Spain
  • Novo Nordisk Investigational Site
    Málaga, 29006, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07014, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07198, Spain
  • Novo Nordisk Investigational Site
    Pozuelo de Alarcon, 28223, Spain
10

References and documents

Publications

  • Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013 Jun;30(6):607-22. doi: 10.1007/s12325-013-0036-1. Epub 2013 Jun 29. PubMed 23812875 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 3 years 11 months after primary completion. A results delay was requested in Jan 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2011
First posted
Mar 30, 2011
Start
Mar 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results delay requested
Jan 17, 2012
Results first posted
Nov 17, 2015
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01326026
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 30, 2011
Start date
Mar 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Nov 17, 2015
Last update
Mar 6, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion